Tenet Healthcare Corporation (NYSE:THC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Tenet Healthcare has a consensus analyst rating of “Moderate Buy”, based on coverage from 22 brokerages. Nineteen analysts rate it a buy, three a hold, and the average 12-month price target is about $244.16.
• Several analysts recently adjusted their outlooks, with price targets mostly lowered but ratings remaining positive. KeyCorp, Wells Fargo, and Stephens all cut targets, while Leerink Partners and Truist maintained bullish ratings and raised targets.
• The company reported strong quarterly earnings, posting EPS of $4.82 versus expectations of $4.21, though revenue slightly missed estimates. Insider selling has also been notable, with executives selling shares over the past 90 days, while institutional investors own most of the stock.

Tenet Healthcare Corporation (NYSE:THC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-two brokerages that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $244.1579.

A number of equities research analysts recently commented on THC shares. KeyCorp lowered their price objective on shares of Tenet Healthcare from $250.00 to $225.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Wells Fargo & Company decreased their price target on shares of Tenet Healthcare from $265.00 to $213.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Stephens decreased their price target on shares of Tenet Healthcare from $275.00 to $260.00 and set an "overweight" rating on the stock in a research note on Monday, May 4th. Leerink Partners raised their price target on shares of Tenet Healthcare from $255.00 to $264.00 and gave the stock an "outperform" rating in a research note on Friday, February 20th. Finally, Truist Financial raised their price target on shares of Tenet Healthcare from $240.00 to $270.00 and gave the stock a "buy" rating in a research note on Tuesday, February 17th.

Insiders Place Their Bets

In other news, insider R. Scott Ramsey sold 8,017 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $232.70, for a total transaction of $1,865,555.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paola M. Arbour sold 6,500 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the transaction, the executive vice president owned 29,291 shares in the company, valued at approximately $6,983,853.13. The trade was a 18.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 46,517 shares of company stock valued at $10,943,111 in the last ninety days. Insiders own 0.81% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Triumph Capital Management purchased a new position in shares of Tenet Healthcare during the 3rd quarter worth about $25,000. Activest Wealth Management purchased a new position in shares of Tenet Healthcare during the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in shares of Tenet Healthcare during the 4th quarter worth about $29,000. William B. Walkup & Associates Inc. purchased a new position in shares of Tenet Healthcare during the 3rd quarter worth about $32,000. Finally, Canada Pension Plan Investment Board purchased a new position in Tenet Healthcare in the second quarter valued at approximately $35,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Tenet Healthcare Price Performance

Shares of NYSE THC opened at $190.37 on Friday. The stock has a market cap of $16.40 billion, a price-to-earnings ratio of 9.90, a PEG ratio of 1.29 and a beta of 1.30. Tenet Healthcare has a 52 week low of $146.60 and a 52 week high of $247.21. The company's 50-day moving average price is $204.80 and its 200 day moving average price is $204.17. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96.

Tenet Healthcare (NYSE:THC - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, beating analysts' consensus estimates of $4.21 by $0.61. The firm had revenue of $5.37 billion for the quarter, compared to analysts' expectations of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, research analysts forecast that Tenet Healthcare will post 17.56 earnings per share for the current fiscal year.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.